Position of the Transparency Council – Uplizna (inebilizumab)

At its meeting on 12 May 2025, the Transparency Council adopted position No. 54/2025 on the apprisal of the drug Uplizna (inebilizumab) under the B.138.FM program. “Treatment of patients with neuromyelitis optica spectrum disorder (NMOSD) (ICD-10: G36.0)”

Publication of the position >>